Delving into the Latest Updates on Dexamethasone with Synapse

Overview

Basic Info

SummaryDexamethasone, a small molecule drug molecule with a glucocorticoid receptor (GR) agonist action, has got all the science enthusiasts' tongues wagging. The GR, which is widely distributed across various cell types, is responsible for myriad physiological responses, including immune and inflammatory responses. This small molecule drug, Dexamethasone, binds to the GR, which sends shockwaves of change through gene expression and protein synthesis, consequently giving inflammation and immune system activity a taste of their own medicine.When it comes to treating various conditions, Dexamethasone takes the crown. This potent drug has proved its mettle in treating an impressive range of conditions, including but not limited to actinic cheilitis, light chain (AL) amyloidosis, ocular inflammation, macular edema, and anaphylaxis. Back in the day, on October 30, 1958, the FDA gave the nod to Dexamethasone. It was a time when Merck & Co., Inc., a pharmaceutical company that hailed from the United States, hit the bull's eye with this innovative drug that promised a bright future.

Drug Type

Small molecule drug

Synonyms

CMIO-DEX, Decadron Phosphate, Dexamethasone Intravitreal Implant

+ [50]

Target

GR

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [13]

Active Indication

Post procedural inflammationMacular EdemaNon-infectious posterior uveitis+ [75]

Inactive Indication

Acute otitis externaAcute otitis mediaAdult Lymphoblastic Lymphoma+ [74]

Originator Organization

Active Organization

+ [36]

Inactive Organization

Otonomy, Inc.

Eli Lilly & Co.Allergan UC

+ [33]

License Organization

AcuCort ABAffaMed Therapeutics (HK) Ltd.

EyePoint, Inc.

+ [14]

Drug Highest PhaseApproved

First Approval Date

United States (30 Oct 1958),

AnaphylaxisEndocrine System DiseasesEye Diseases+ [7]

RegulationOrphan Drug (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H29FO5

InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N

CAS Registry50-02-2

This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.

Start Date01 Dec 2026

Sponsor / Collaborator

Universitätsklinikum Hamburg-Eppendorf

[+2]

NCT07870278

/ Not yet recruitingPhase 1

A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-6255 Monotherapy in Advanced Solid Tumors

Researchers are looking for new ways to treat advanced and recurrent endometrial cancer (EC) and ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Recurrent means the cancer came back after treatment.
MK-6255 is a trial medicine designed to treat advanced and recurrent EC and OC. This trial is the first time that researchers will give MK-6255 to people.
The goals of this trial are to learn about:
* The safety of MK-6255 and if participants tolerate it. Tolerate means participants will receive the trial medicine unless they need to stop it due to health problems.
* What happens to different dose levels (amounts) of MK-6255 in the body over time.

Start Date13 Nov 2026

Sponsor / Collaborator

Merck Sharp & Dohme LLC

NCT07837674

/ Not yet recruitingNot ApplicableIIT

Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine

The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

Start Date01 Nov 2026

Sponsor / Collaborator-

100 Clinical Results associated with Dexamethasone

Login to view more data

100 Translational Medicine associated with Dexamethasone

Login to view more data

100 Patents (Medical) associated with Dexamethasone

Login to view more data

67,560

Literatures (Medical) associated with Dexamethasone

01 Mar 2027·Value in Health Regional Issues

Cost-Minimization Analysis of Intravenous and Subcutaneous Daratumumab in Patients With Multiple Myeloma: A Societal and Healthcare System Perspective

Article

Author: Fantelli, Valentina ; Temporin, Francesca ; Venturini, Francesca ; Riccoboni, Debora ; Zambello, Renato ; Berti, Giacomo

OBJECTIVES:

We compared costs of daratumumab (DARA) subcutaneous (SC) versus intravenous (IV) from societal and healthcare system perspectives.

METHODS:

We performed a cost-minimization analysis over 24 months using real-world weight distribution data from 304 patients treated in 2024. IV drug costs were weighted by patient distribution across 14 weight categories (6.25 kg intervals). We analyzed 4 patient scenarios (employed/unemployed, with/without caregiver) and 2 regimens (DARA-lenalidomide-dexamethasone, DARA-bortezomib-dexamethasone). Costs included drug acquisition, preparation materials, personnel time, and productivity losses. Probabilistic sensitivity analysis (10 000 Monte Carlo simulations) assessed robustness to weight distribution uncertainty. Break-even analysis identified weight thresholds at which formulations were cost equivalent.

RESULTS:

Initial IV administration required 1104 minutes versus 22 minutes for SC; subsequent IV administrations required 392 minutes. Weighted average IV drug cost was €5579 versus €5652 for SC. From a societal perspective, SC generated savings of €1125 to €11 899 across all scenarios. Probabilistic analysis showed 100% probability of SC cost saving (mean €5839; 95% CI €2204-€14 317), with weight distribution uncertainty contributing only 2% of total cost variability. Break-even analysis showed IV was marginally cheaper only in patients < 68.75 kg (42.9% of cohort). From the healthcare provider perspective, SC generated higher net revenues (€308 versus €175 per administration); payer costs remained neutral (€315 per administration regardless of route).

CONCLUSIONS:

SC DARA provides robust economic advantages across all regimens, patient scenarios, and time horizons. Despite marginal cost advantages for IV in less weight patients, the comprehensive clinical and operational benefits strongly support SC as the preferred administration route.

01 Feb 2027·TISSUE & CELL

Shionone attenuates lipopolysaccharide-induced acute lung injury by inhibiting ferroptosis via Keap1/Nrf2/SLC7A11/GPX4 signaling pathway

Article

Author: Sun, Yang ; Han, Zhipeng ; Yuan, Peizhi ; Arad, Maor ; Zhong, Mengling ; Zhang, Tianyao ; Feng, Mingmei ; Chen, Jiaxi ; Zhang, Qi

Acute lung injury (ALI) is a respiratory disease with a high mortality rate. Shionone, derived from the Chinese herbal medicine Aster tataricus, has anti-inflammatory and antioxidant effects. However, its protective effect on ALI remains unclear. In this study, we aimed to assess the protective effect of shionone on lipopolysaccharide (LPS)-induced ALI and to elucidate its underlying mechanisms. In this study, male C57BL/6 mice aged 8-10 weeks were randomly divided into five groups (10 mice per group) including control group, LPS group, LPS + shionone (50 mg/kg) group, LPS + shionone (100 mg/kg) group, and LPS + Dexamethasone (1 mg/kg) group. In mice with LPS-induced ALI, shionone significantly reduced lung index, lung wet/dry weight ratio, production of inflammatory cytokines, nitric oxide (NO) content, malondialdehyde (MDA) production, and increased superoxide dismutase (SOD) activity and nicotinamide adenine dinucleotide phosphate (NADPH) level. Shionone improved lung histopathological injury by inhibiting inflammatory cell infiltration and edema in LPS-induced ALI in mice. In vitro, shionone inhibited oxidative stress and inflammation in LPS-induced BEAS-2B cells. Shionone improved the protein expression of anti-ferroptosis proteins, including glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11), in mice lung tissues and BEAS-2B cells. Additionally, GC-MS-based metabolomic analysis showed that shionone increased the levels of various metabolites, such as fructose, glucose, and lactic acid. Shionone ameliorated LPS-induced ALI by downregulating Kelch-like ECH-associated protein 1 (Keap1) and upregulating Nuclear factor erythroid 2-related factor 2 (Nrf2), Heme oxygenase-1 (HO-1), and quinone oxidoreductase 1 (NQO1) in both in vivo and in vitro study. In conclusion, this study demonstrated that shionone mitigated LPS-induced ALI by inhibiting ferroptosis through regulation of Keap1/Nrf2/SLC7A11/GPX4 pathway, indicating that shionone may be a promising agent for ALI.

01 Feb 2027·JOURNAL OF ETHNOPHARMACOLOGY

Ainsliaea fragrans Champ. alleviates endometritis by modulating the STING-TBK1-IRF3 and NLRP3 inflammasome signaling pathway

Article

Author: Wu, Yanyu ; Lui, Jun ; Fu, Wenyan ; Zhuang, Yuan ; Cheng, Yufen

ETHNOPHARMACOLOGICAL RELEVANCE:

Ainsliaea fragrans Champ. (AFC) is a traditional Chinese medicine used for gynecological inflammations. However, its specific effects and molecular mechanisms in treating endometritis remain unclear.

AIM OF THE STUDY:

The primary objective of this work was to assess the protective effects of AFC in a murine model of LPS-induced endometritis and to decode the signaling pathways involved.

MATERIALS AND METHODS:

Mice with LPS-induced endometritis were given AFC (0.5, 1, 2 g/kg) or dexamethasone to assess its protective effects. Uterine pathological changes, inflammatory cytokine levels, and immune cell infiltration were assessed. Complementary transcriptomic and proteomic analyses were performed to identify key pathways, followed by in vitro validation in THP-1 cell using mitochondrial function assays, immunofluorescence, Western blotting, and co-immunoprecipitation.

RESULTS:

AFC significantly alleviated LPS-induced uterine swelling, diminished the levels of IL-1β and TNF-α, ameliorated histopathological damage, and decreased neutrophil and macrophage infiltration. Integrative omics analysis identified the cytosolic DNA-sensing and NOD-like receptor signaling pathways as core mechanisms. The anti-inflammatory mechanism of AFC involved multifaceted regulation of the STING-TBK1-IRF3 signaling and NLRP3 inflammasome pathways. On one hand, AFC maintained mitochondrial homeostasis by upregulating membrane potential, attenuating ROS overproduction, and blocking mtDNA escape into the cytosol, which in turn inactivated the STING-TBK1-IRF3 cascade. On the other hand, AFC reduced NLRP3 and cleaved Caspase-1 abundance, abrogated their interaction, and thus impeded NLRP3 inflammasome complex formation.

CONCLUSION:

AFC alleviates LPS-induced endometritis through the STING-TBK1-IRF3 signaling pathway and the NLRP3 inflammasome signaling pathway, representing a promising candidate drug with early-interventional or preventive potential.

1,849

News (Medical) associated with Dexamethasone

15 Oct 2026

·www.biospace.com

Eclipse Life Sciences Announces Positive Topline Results from Phase 2 BETTIS-1 Study Evaluating EC-104 for Diabetic Macular Edema (DME)

RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc. , a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, today announced positive topline results from its BETTIS-1 Phase 2 clinical trial comparing EC-104 fluocinolone acetonide (FA) extended release versus Ozurdex® for the treatment of diabetic macular edema (DME). EC-104 is a novel, completely biodegradable intravitreal corticosteroid implant engineered to deliver approximately six months of durable drug release. The BETTIS‑1 trial met its primary endpoint, demonstrating a favorable safety pro both EC-104 formulations compared to Ozurdex®. Secondary endpoints showed superior clinically meaningful and durable improvement in both best corrected visual acuity and OCT central subfield thickness at 24 weeks, when compared to Ozurdex®. The superiority of EC-104 was demonstrated in a study population of subjects with a previous suboptimal response to anti-VEGF therapy, which represents a significant unmet need and commercial opportunity. “These results position EC-104 as a highly competitive candidate in the DME landscape,” said Scott Cousins, MD, CEO and VP for Research and Development at Eclipse Life Sciences . “The six-month durability, consistent anatomical response, and strong safety pro EC-104’s potential to meaningfully reduce treatment burden. EC-104 continues to show promise as a differentiated corticosteroid option for patients who need longer lasting treatment. We believe these data support advancement into Phase 3 and create a compelling opportunity for strategic collaboration.” Phase 2 BETTIS-1 Topline Findings Primary Endpoint Achieved: EC-104 demonstrated a favorable safety pro low rates of treatment-related adverse events and no unexpected safety signals. Durable Anatomical Response: Both EC-104 formulation groups showed sustained reductions in central subfield thickness (CST) through 24 weeks, consistent with the implant’s six-month release profile. Clinical Benefit in Anti-VEGF-Resistant Subjects: Subjects with documented suboptimal response to prior anti-VEGF therapy exhibited clinically meaningful anatomical improvements, reinforcing EC-104’s potential role as an alternative treatment. Intraocular Pressure (IOP) Profile: Patients with prior corticosteroid tolerance maintained acceptable IOP outcomes in both formulation arms. “These results highlight the potential of EC-104 to reduce treatment burden for patients who struggle with frequent injections and insufficient response to anti-VEGF therapies,” said Victor H. Gonzalez, MD , retina specialist and Founder, Gulf Coast Eye Institute in McAllen, Texas. “An authentic six-month sustained release intravitreal corticosteroid option will be a significant advancement for this population.” Strategic Opportunity With strong Phase 2 data and a well-defined path for late-stage clinical development, regulatory approval and commercialization, Eclipse Life Sciences is exploring partnership opportunities to accelerate Phase 3 initiation and global commercialization. EC-104’s pro it as a differentiated entrant in the multi-billion-dollar DME market where durability and efficacy drive adoption. Next Steps Eclipse Life Sciences plans to engage with regulatory authorities to discuss Phase 3 development of EC-104 and expects to initiate a pivotal program in 2027. Full BETTIS-1 data will be presented at an upcoming ophthalmology conference and will be submitted for publication in a peer-reviewed journal. About Diabetic Macular Edema (DME) DME is the leading cause of vision loss among working-age adults. Although standard of care is initiating treatment with anti-VEGF therapies, many patients experience suboptimal response and require alternative treatments. Intravitreal corticosteroids play a critical role in addressing neuroinflammatory pathways in DME. About Eclipse Life Sciences, Inc. Eclipse Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases. In addition to EC-104, Eclipse is advancing EC-303 for intermediate dry age-related macular degeneration (AMD) and EC-501, a six-month anti-VEGF therapy candidate for wet AMD, DME, and macular edema following retinal vein occlusion (RVO). Investigational product. Not approved by regulatory authorities. For media inquiries: info@eclipselifesciences.com Forward Looking Statements: This press release contains forward looking statements. Actual results may differ materially from those expressed or implied by such statements. Factors that could cause actual results to differ include clinical trial outcomes, regulatory decisions, and market conditions.

Clinical ResultPhase 2

09 Oct 2026

·www.globenewswire.com

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of October 5, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 70,150 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 22,900 shares of Ocular’s common stock. The stock option awards have an exercise price of $7.25 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares for each award vesting on the one-year anniversary of the applicable recipient’s commencement of employment, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & MediaOcular Therapeutix, Inc.Bill SlatteryVice President, Investor Relationsbslattery@ocutx.com

Phase 3Phase 2

09 Oct 2026

·www.biospace.com

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 9, 2026

BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of October 5, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 70,150 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 22,900 shares of Ocular’s common stock. The stock option awards have an exercise price of $7.25 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares for each award vesting on the one-year anniversary of the applicable recipient’s commencement of employment, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com

Phase 3Phase 2

100 Deals associated with Dexamethasone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00292	Dexamethasone	D07AB19 H02AB02 D10AA03	DB01234

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Macular Edema	United States	AbbVie, Inc.	11 Mar 2026
Non-infectious posterior uveitis	United States	AbbVie, Inc.	11 Mar 2026
Immunoglobulin Light-Chain Amyloidosis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	25 Aug 2021
Immunoglobulin Light-Chain Amyloidosis	Japan	Sandoz KK	25 Aug 2021
Ocular inflammation	United States	Ocular Therapeutix, Inc.	30 Nov 2018
Ophthalmologic surgical procedures	United States	Ocular Therapeutix, Inc.	30 Nov 2018
Post procedural inflammation	United States	EyePoint, Inc.	09 Feb 2018
Post procedural inflammation	United States	EyePoint Pharmaceuticals US, Inc.	09 Feb 2018
Diabetic macular oedema	European Union	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Diabetic macular oedema	Iceland	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Diabetic macular oedema	Liechtenstein	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Diabetic macular oedema	Norway	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Retinal vein occlusion-related macular edema	European Union	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Retinal vein occlusion-related macular edema	Iceland	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Retinal vein occlusion-related macular edema	Liechtenstein	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Retinal vein occlusion-related macular edema	Norway	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	European Union	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	Iceland	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	Liechtenstein	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	Norway	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain, Postoperative	NDA/BLA	Singapore	AffaMed Therapeutics Co., Ltd.	19 Feb 2024
Pain	Phase 3	China	Ocular Therapeutix, Inc.	17 Aug 2023
Pain	Phase 3	China	AffaMed Therapeutics Co., Ltd.	17 Aug 2023
Uveitis	Phase 3	China	Ocumension Therapeutics	22 Aug 2022
Retinitis	Phase 3	United States	AbbVie, Inc.	12 Oct 2021
Glaucoma	Phase 3	-	Ocular Therapeutix, Inc.	01 Nov 2020
Glaucoma, Open-Angle	Phase 3	-	Ocular Therapeutix, Inc.	01 Nov 2020
Plasmacytoma	Phase 3	United States	Millennium Pharmaceuticals, Inc.	29 Nov 2016
Meniere Disease	Phase 3	United States	Otonomy, Inc.	27 Oct 2015
Eye Pain	Phase 3	-	Ocular Therapeutix, Inc.	01 Apr 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01745588 (CTgov)	Phase 2	Refractory Multiple Myeloma	23	stem cell+Pomalidomide+Clarithromycin (Clarithromycin + Pomalidomide + Dexamethasone + Stem Cell)	ejhatfiagx = hakdsembbo hkvsnlifvi (hrywcundko, bzercjsnhm - apvohsfhio) View more	-	25 Sep 2026
				Pomalidomide+Clarithromycin+Dexamethasone (Clarithromycin + Pomalidomide + Dexamethasone Alone)	ejhatfiagx = tibbfbjowd hkvsnlifvi (hrywcundko, joouvsbgsm - hiviwgatuj) View more
NCT04484623 (DREAMM-8, IMS2026)	Phase 3	Relapse multiple myeloma	302	Belantamab Mafodotin+Pomalidomide+Dexamethasone	qnqjyyxdbq(loxsesjpiz) = fffwqtbted nnberspvbb (kgkoqfvcae )	Positive	23 Sep 2026
				Pomalidomide+Bortezomib+Dexamethasone	qnqjyyxdbq(loxsesjpiz) = fwruemmvzm nnberspvbb (kgkoqfvcae )
NCT04484623 (DREAMM-8, IMS2026)	Phase 3	Multiple Myeloma Second line	159	Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd)	ggsjbbeqzp(atfargxnfa) = jqpgicexks ylcdcdokgp (bqqvoscino ) View more	Positive	23 Sep 2026
				Pomalidomide, Bortezomib, and Dexamethasone (PVd)	ggsjbbeqzp(atfargxnfa) = mgcaaxtgja ylcdcdokgp (bqqvoscino ) View more
NCT05590923 (CTgov)	Phase 4	Chemotherapy-induced nausea and vomiting \| Nausea \| Vomiting	23	DEX (Dexamethasone) (DEX (Dexamethasone))	uaddhgrvym = noyhyarzfq uoaumheufm (stshbuqnkq, kxepsfwdnx - tetxocbhwf) View more	-	02 Sep 2026
				OLA (Olanzapine) (OLA (Olanzapine))	uaddhgrvym = jwdjdljlfy uoaumheufm (stshbuqnkq, ovoiimkmlc - myouvmylsw) View more
NCT05018091 (CTgov)	Phase 4	-	438	Dexamethasone 4mg (Group 1)	hlbpyzsmsh(fxigkryllm) = tsntghupjy vcswiiugbz (pzniluddyu, 168.9) View more	-	03 Aug 2026
				Dexamethasone 8 Mg/mL Injectable Suspension (Group 2)	hlbpyzsmsh(fxigkryllm) = rwynpityxt vcswiiugbz (pzniluddyu, 122.3) View more
NCT06128369 (OPTIMIZE-2, CTgov)	Phase 3	Eye Pain \| Ocular inflammation \| Macular Edema ... View more	117	OCS-01 (OCS-01)	jytndewleg = qzxjpxkypf rzrectbslo (sydkpzeain, fkzrxgutzp - zyqzcxuvfi) View more	-	30 Jul 2026
				Vehicle (Vehicle)	jytndewleg = zrxvkxcfek rzrectbslo (sydkpzeain, qpqbrmpfrc - qtgnnloynr) View more
NCT02516423 (CTgov)	Phase 3	Plasmacytoma	11	Lenalidomide+ixazomib+zoledronic acid+dexamethasone (Ixazomib + Lenalidomide + Dexamethasone + Zoledronic Acid)	acnhtldbul = gissngstxv nadpcepira (iuobksotpm, hvkejwefla - kqkhpadgit) View more	-	30 Jun 2026
				zoledronic acid (Zoledronic Acid)	acnhtldbul = hlkhajfcqp nadpcepira (iuobksotpm, dqynaumkxz - azefepeole) View more
NCT07150104 (CTgov)	Phase 1/2	Multiple Myeloma	14	Mafodotin+Nirogacestat+Pomalidomide+Dexamethasone+Belantamab	dopulsevyv = xxesigctty taiereokex (xfrqpxanrd, fkqcqslaph - ypiipybcax) View more	-	25 Jun 2026
NCT07150091 (CTgov)	Phase 1/2	Multiple Myeloma	20	Mafodotin+Lenalidomide+Nirogacestat+Dexamethasone+Belantamab (0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone)	jaowuhwvdd = pdjreofeya snnipcfwbt (dgosnimglg, jdoydvlykr - zcdmjkbhtm) View more	-	16 Jun 2026
				Mafodotin+Lenalidomide+Nirogacestat+Dexamethasone+Belantamab (1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone)	jaowuhwvdd = hxqywnlfdz snnipcfwbt (dgosnimglg, odjbzbonxn - erugdusgkr) View more
NCT05552976 (SUCCESSOR-2, EHA2026)	Phase 3	Relapse multiple myeloma	479	Mezigdomide 1.0 mg + Kd	zqbjrrmcgp(ksvulvbfrg) = gnxcjiexkg cbeiycppnu (uytwvsunku ) View more	Positive	02 Jun 2026
				Kd	zqbjrrmcgp(ksvulvbfrg) = ouphwbpdks cbeiycppnu (uytwvsunku ) View more